Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow ANL by emailGet an email when ANL pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ANL, unsubscribe in one click. Privacy
📣 What ANL Says Is Next
second half of 2027 · “We look forward to advancing this asset globally and remain on track to report full Phase Ia data in the second half of 2027.” This global phase I trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AN4035 as monotherapy and in combination with cetuximab in patients with CEACAM5-enriched, RAS-addicted solid tumors.”
Company press release, Sep 8, 2026 · SEC filing
2H26 · “AN4035: Dosing of first patient in global Phase I trial is expected in 2H26, with initial clinical data in 2H27”
Company press release, Aug 14, 2026 · SEC filing
1H27 · “AN9025: Initial Phase Ia clinical data from the QD arm, and possible early look at QW arm, are expected in 1H27”
Company press release, Aug 14, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ANL and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.